Treatment of relapsed/refractory chronic lymphocytic leukemia with Zanubrutinib after progressing on other BTK inhibitors

Nkolika Nwankwo; Aswanth Reddy; Swarup Kumar; Maha Zafar

doi:10.1016/j.lrr.2024.100459

Treatment of relapsed/refractory chronic lymphocytic leukemia with Zanubrutinib after progressing on other BTK inhibitors

Leuk Res Rep. 2024 Apr 16:21:100459. doi: 10.1016/j.lrr.2024.100459. eCollection 2024.

Authors

Nkolika Nwankwo¹, Aswanth Reddy², Swarup Kumar³, Maha Zafar¹

Affiliations

¹ Department of Internal Medicine, Mercy Clinic, 7001 Rogers ave, Fort Smith, AR 72903, USA.
² Department of Hematology and Oncology, Mercy Clinic, 7001 Rogers ave, Fort Smith, AR 72903, USA.
³ Department of Hematology and Oncology, University of Connecticut Health, 263 Framington ave, Farmington, CT 06030, USA.

Abstract

Chronic Lymphocytic Leukemia (CLL) is the most common type of leukemia in the US, representing approximately 1.1% of all new cancers diagnosed. Most patients with CLL can be monitored without treatment, and the indicated treatment options include a CD20 monoclonal antibody with or without bruton tyrosine kinase (BTK) inhibitors, phosphatidylinositol 3-kinase (PI3K) inhibitors, and B-cell lymphoma 2 (BCL2) antagonists. We review the case of a 77-year-old female with a long-standing history of CLL predominant lymphocytosis, transfusion -independent anemia, and thrombocytopenia. Patient responded to zanubrutinib after initial failure of idelalisib, rituximab, and acalabrutinib and venetoclax.

Keywords: Btk inhibitors; Cancer therapeutics; Cll; Leukemia; Zanubrutinib.

Publication types

Case Reports